BR112021017635A2 - Composições e métodos para tratar a doença de huntington - Google Patents
Composições e métodos para tratar a doença de huntingtonInfo
- Publication number
- BR112021017635A2 BR112021017635A2 BR112021017635A BR112021017635A BR112021017635A2 BR 112021017635 A2 BR112021017635 A2 BR 112021017635A2 BR 112021017635 A BR112021017635 A BR 112021017635A BR 112021017635 A BR112021017635 A BR 112021017635A BR 112021017635 A2 BR112021017635 A2 BR 112021017635A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- compositions
- methods
- treating huntington
- treating
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815647P | 2019-03-08 | 2019-03-08 | |
| PCT/US2020/021652 WO2020185651A2 (en) | 2019-03-08 | 2020-03-09 | Compositions and methods for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017635A2 true BR112021017635A2 (pt) | 2021-11-09 |
Family
ID=72428020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017635A BR112021017635A2 (pt) | 2019-03-08 | 2020-03-09 | Composições e métodos para tratar a doença de huntington |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3935167A2 (zh) |
| JP (1) | JP2022524383A (zh) |
| KR (1) | KR20220002882A (zh) |
| CN (1) | CN113924364A (zh) |
| AU (1) | AU2020238872A1 (zh) |
| BR (1) | BR112021017635A2 (zh) |
| CA (1) | CA3132388A1 (zh) |
| IL (1) | IL286083A (zh) |
| SG (1) | SG11202109180RA (zh) |
| WO (1) | WO2020185651A2 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024035952A1 (en) * | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900016B1 (en) * | 2000-09-08 | 2005-05-31 | Applera Corporation | Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof |
| US7214786B2 (en) * | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| US20080274989A1 (en) * | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| US9441221B2 (en) * | 2007-03-30 | 2016-09-13 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
| CA2713458A1 (en) * | 2008-01-29 | 2009-08-06 | Proyecto De Biomedicina Cima, S.L. | Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner |
| AU2015252117A1 (en) * | 2008-04-11 | 2015-11-26 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP3277814B1 (en) * | 2015-04-03 | 2020-06-03 | University of Massachusetts | Oligonucleotide compounds for targeting huntingtin mrna |
-
2020
- 2020-03-09 WO PCT/US2020/021652 patent/WO2020185651A2/en unknown
- 2020-03-09 SG SG11202109180RA patent/SG11202109180RA/en unknown
- 2020-03-09 EP EP20770560.9A patent/EP3935167A2/en not_active Withdrawn
- 2020-03-09 JP JP2021553317A patent/JP2022524383A/ja active Pending
- 2020-03-09 CA CA3132388A patent/CA3132388A1/en active Pending
- 2020-03-09 BR BR112021017635A patent/BR112021017635A2/pt not_active Application Discontinuation
- 2020-03-09 AU AU2020238872A patent/AU2020238872A1/en not_active Abandoned
- 2020-03-09 CN CN202080019190.5A patent/CN113924364A/zh active Pending
- 2020-03-09 KR KR1020217032259A patent/KR20220002882A/ko unknown
-
2021
- 2021-09-02 IL IL286083A patent/IL286083A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL286083A (en) | 2021-10-31 |
| CN113924364A (zh) | 2022-01-11 |
| EP3935167A2 (en) | 2022-01-12 |
| JP2022524383A (ja) | 2022-05-02 |
| WO2020185651A3 (en) | 2020-10-29 |
| WO2020185651A2 (en) | 2020-09-17 |
| AU2020238872A1 (en) | 2021-09-16 |
| KR20220002882A (ko) | 2022-01-07 |
| SG11202109180RA (en) | 2021-09-29 |
| CA3132388A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007627A2 (pt) | Compostos moduladores do glp-1r | |
| BR112017028194A2 (pt) | moduladores de diaciglicerol aciltransferase 2 (dgat2) | |
| BR112021006392A2 (pt) | moduladores da alfa-1 antitripsina | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| PH12021550558A1 (en) | Modulators of pnpla3 expression | |
| JOP20210158A1 (ar) | مُعَدِّلات التعبير الجيني عن hsd17b13 | |
| PH12019502174A1 (en) | Modulators of pcsk9 expression | |
| MX2020012497A (es) | Moduladores de la expresion de apol1. | |
| MX2020002322A (es) | Compuestos y composiciones para la inhibicion de ire1. | |
| BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| MD3638271T2 (ro) | Compoziții cuprizând tulpini bacteriene | |
| MA48939B1 (fr) | Compositions comprenant des souches bactériennes | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| PH12021551053A1 (en) | Modulators of irf5 expression | |
| BR112022007010A2 (pt) | Terapia gênica para doença de alzheimer | |
| BR112021023144A2 (pt) | Compostos de oxatiazina para inibir gapdh | |
| BR112021017635A2 (pt) | Composições e métodos para tratar a doença de huntington | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| MX2020007369A (es) | Moduladores de la expresion de dnm2. | |
| BR112019027387A8 (pt) | Composições imunogênicas | |
| BR112021019127A2 (pt) | Composições e métodos para tratar distúrbios neurodegenerativos | |
| EA202190045A1 (ru) | Составы/композиции, содержащие ибрутиниб | |
| EA202191657A1 (ru) | Модуляторы экспрессии hsd17b13 | |
| BR112021022501A2 (pt) | Composições compreendendo cepas bacterianas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |